Dr. Robert Robey (National Cancer Institute, NIH) Novel inhibitors of ABCG2 identified by high-throughput screening analysis
Dr. Demian Park(Phylonix) Zebrafish: A predictive model for assessing modulators of P-glycoprotein efflux
Dr. Anne-Marie Bleau (Memorial Slaon-Kettering Cancer Center) Loss of PTEN increases ABCG2 activity in glioma tumor stem cells and contributes to the MDR phenotype
Dr. Daotai Nie (Southern Illinois University School of Medicine) The role of PXR in cancer multidrug resistance
Dr. Tianyong Zhao (University of Kentucky) Multidrug resistance-associated protein 1 (MRP1) localizes in junction of cultured HL1 cells and mediates doxorubicin induced stress signal transmission between cells
Welcome and introduction to scope of the meeting - Dr. Suresh Ambudkar
Keynote speaker: Dr. Michael Gottesman - Current status of MDR and ABC transporters
Dr. Suresh Ambudkar - Mechanism of action of MDR-linked ABC drug transporters
Dr. Robert Innis - Positron emission Tomographic imaging of drug efflux transporters
Dr. David Miller -Regulation of P-glycoprotein and other ABC drug transporters at the bloodbrain barrier
Dr. Demian Park-Zebrafish: A predictive model for assessing modulators of P-glycoprotein efflux
Dr. Zhe-Sheng (Jason) Chen- Tyrosine kinase inhibitors as modulators of multidrug resistance in cancer
Dr. Maria Baer - Polymorphisms within PfMDR1 alter the substrate specificity for antimalarial drugs in Plasmodium falciparum
Dr.Maria Baer-Clinical and therapeutic implications of multidrug resistance-associated ABC drug transporters
Ms. Maria Fabiana De Rosa- Inhibition of MDR1 as possible therapy for Fabry Disease
Dr. Daotai Nie-The role of PXR in cancer multidrug resistance
Dr. Gilbert Burckart-Drug-drug interactions and regulatory implications for membrane transporter substrates in drug development
Dr. Anne-Marie Bleau-Loss of PTEN increases ABCG2 activity in glioma tumor stem cells and contributes to the MDR phenotype
Dr. Robert Robey-Novel Inhibitors of ABCG2 identified by high-throughput screening analysis
Dr. Tian-Yong Zhao - Multidrug resistance-associated protein 1 (MRP1) localizes in junction of cultured HL1 cells and mediates doxorubicin induced stress signal transmission between cells
Reception and poster session
Posters will be judged. The winner will receive up to $150 off their registration for a future Abcam conference or an antibody from the Abcam catalog.
Posters must be no larger than four feet tall by eight feel wide.
The registration fee includes lunch, coffee, reception, and abstract book.
Students are categorized as those in full-time education at the time of registering. Proof of student status may be requested.
If you are paying via American Express, please contact Katie via email or at 617-577-4263 since we cannot take the cards online at the moment.
Abcam is proud to have the following companies exhibiting at the meeting.
Absorption Systems Absorption Systems® is “the drug absorption company”. A preclinical ADME contract research organization, we are also developing a suite of proprietary human cell lines, CellPort Technologies™ for the definitive identification and characterization of drug-transporter interactions. These models are used in the bidirectional transport assay format the FDA requires for submission.
Applied Biosystems Applied Biosystems has demonstrated its position as a technology leader and driving force in the changing dynamics of the life science marketplace. The Applied Biosystems business is focused on the following markets: basic research, commercial research (pharmaceutical and biotechnology) and standardized testing, including forensic human identification, paternity testing and food testing.
Cancellation Terms and Conditions Delegates are advised to ensure they have adequate travel insurance to cover their attendance at the conference in case of incident, or cancellation due to circumstances beyond Abcam’s control.
All fees paid to Abcam, including registration are non-refundable.